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A bioavailable cathepsin S nitrile inhibitor
abrogates tumor development
Richard D. A. Wilkinson1, Andrew Young1, Roberta E. Burden1, Rich Williams2* and Christopher J. Scott1*
Abstract
Background: Cathepsin S has been implicated in a variety of malignancies with genetic ablation studies
demonstrating a key role in tumor invasion and neo-angiogenesis. Thus, the application of cathepsin S inhibitors
may have clinical utility in the treatment of cancer. In this investigation, we applied a cell-permeable dipeptidyl
nitrile inhibitor of cathepsin S, originally developed to target cathepsin S in inflammatory diseases, in both in vitro
and in vivo tumor models.
Methods: Validation of cathepsin S selectivity was carried out by assaying fluorogenic substrate turnover using
recombinant cathepsin protease. Complete kinetic analysis was carried out and true Ki values calculated. Abrogation
of tumour invasion using murine MC38 and human MCF7 cell lines were carried out in vitro using a transwell
migration assay. Effect on endothelial tube formation was evaluated using primary HUVEC cells. The effect of inhibitor
in vivo on MC38 and MCF7 tumor progression was evaluated using cells propagated in C57BL/6 and BALB/c mice
respectively. Subsequent immunohistochemical staining of proliferation (Ki67) and apoptosis (TUNEL) was carried out
on MCF7 tumors.
Results: We confirmed that this inhibitor was able to selectively target cathepsin S over family members K, V, L and B.
The inhibitor also significantly reduced MC38 and MCF7 cell invasion and furthermore, significantly reduced HUVEC
endothelial tubule formation in vitro. In vivo analysis revealed that the compound could significantly reduce tumor
volume in murine MC38 syngeneic and MCF7 xenograft models. Immunohistochemical analysis of MCF7 tumors
revealed cathepsin S inhibitor treatment significantly reduced proliferation and increased apoptosis.
Conclusions: In summary, these results highlight the characterisation of this nitrile cathepsin S inhibitor using in vitro
and in vivo tumor models, presenting a compound which may be used to further dissect the role of cathepsin S in
cancer progression and may hold therapeutic potential.
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Background
Proteases are involved in a variety of physiological pro-
cesses wherein they facilitate the irreversible hydrolysis of
substrate proteins [1]. The scope of protease activity pro-
vided by the genome is reflected by the identification of
more than 500 known protease genes [2, 3]. Unsurprisingly,
due to the role proteases play in areas such as signalling, re-
ceptor activation and chemokine/cytokine processing, dys-
regulated proteases are frequently involved in pathological
conditions via various mechanisms [4–6]. As a result, there
has been a surge in the development of inhibitors to fur-
ther elucidate the role of proteases in disease [7–10].
Cathepsin S (CTSS) is a lysosomal protease which has
been shown to be expressed in a number of inflammatory
conditions including autoimmune, cardiovascular disease
and cancer [11, 12]. In cancer, elevated CTSS expression
has been associated with poorer outcome in grade IV astro-
cytoma and colorectal carcinomas [13, 14]. Furthermore,
genetic ablation of CTSS in murine models resulted in di-
minished tumorigenicity [15, 16]. CTSS has been shown to
cleave a variety of substrates including extracellular matrix
(ECM) proteins, pro- and anti-angiogenic peptides and
junctional adhesion proteins indicating a role in invasion,
angiogenesis and metastasis [17–19].
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Increased CTSS expression at the tumor site has been
reported to be a result of tumor associated macrophage
(TAM) recruitment, with the presence of CTSS dependent
on IL-4, indicative of an M2 phenotype [20–22]. In
addition to TAMs, tumor cells and recruited stromal cells
can contribute CTSS to the microenvironment,
highlighted through clinical observations [13] and investi-
gations using stratified murine tumor gene depletion
models [16, 19].
Previously, we have focussed our attention on develop-
ing and assessing inhibitors that can inhibit CTSS protein
that is secreted into the tumor microenvironment, using
protein based inhibitors such as a propeptide fusion pro-
tein [23] as well as an antibody inhibitor, FSN0503, which
displays high selectivity towards CTSS [24]. However, our
recent findings that CTSS may be able to promote pro-
tumorigenic signalling through lysosomal cleavage of
CD74 (invariant chain) to modulate CCL2 expression [6],
highlights that an inhibitor that can target both extra- and
intracellular activities may also have utility. To investigate
this, we have now synthesised a small molecule inhibitor
that was originally developed by Merck-Frosst [25]. This
dipeptidyl nitrile inhibitor (Compound 6) was shown to
possess 225-fold selectivity toward CTSS over cathepsin
K, and a more than 560-fold selectivity against cathepsin
L and cathepsin B [26]. Furthermore, it has previously
been utilised in vivo studying lung granulomas and ath-
erosclerotic lesions, demonstrating cell penetration and
cross species reactivity [27, 28].
This investigation describes the application of this com-
pound for the first time in tumor models. Previous studies
have validated IC50 values for compound 6 versus CTSS,
K, L and B. Here, we profile true Ki values for the inhibitor
towards CTSS over the other related cathepsins confirm-
ing selectivity of compound 6. We also show that com-
pound 6 can reduce block intracellular cleavage of known
CTSS substrate lip10; attenuate colorectal and breast cell
line invasion, and inhibit endothelial tube formation. Se-
lectivity of the inhibitor to CTSS was confirmed using a
cellular MC38 shRNA knock-down model. Finally, we
demonstrate that compound 6 has therapeutic utility in
murine models, blocking tumor progression using both a
colorectal syngeneic and a breast xenograft tumor model.
Methods
Cell culture
Raji (human B cell) (ATCC), MC38 (murine colorectal
carcinoma) (ATCC) and MCF7 (human breast adenocar-
cinoma) (ATCC) were cultured in media containing 10 %
FCS (Sigma Aldrich, UK) and 50 U/mL Penicillin and 50
μg/ml streptomycin (Life Technologies, UK). HUVEC
(Cellworks) primary cells were cultured in large vessel
endothelial cell growth medium (Cellworks) containing
human large vessel endothelial cell growth supplement
(KC1016) and antibiotic supplement (KC1019). Cells were
maintained in 5 % CO2 at 37 °C. MCF7 cell line was vali-
dated by STR profiling by LGC Standards in May 2011.
All subsequent cells have only been taken from these vali-
dated stocks.
Synthesis of compound 6
To a solution of Boc-Cys-OMe (0.88g, 3.74 mmol) in
DMF (30 mL) at 0 °C was added K2CO3 (0.51 g, 3.74
mmol) and MeI (0.23 mL, 3.74 mmol) warmed to room
temperature and stirred for 20 h. The reaction was di-
luted with a 9:1 water/NH4Cl (2 M aq. Solu.) and ex-
tracted with EtOAc (×2). The organic extracts were
washed with 5 % brine, dried over Na2SO4 and concen-
trated. Dissolved in MeOH (10 mL) and added to a 2 N
methanolic-HCl solution and stirred at room
temperature for 3 h. The mixture was concentrated and
the solid was washed with MTBE (50 mL ×3) to afford
(S)-methyl 2-amino-3-(methylthio)propanoate hydro-
chloride) as a clear light yellow oil (0.62 g, 90 %). Dis-
solved in MeOH (8 mL) and cooled to -78 °C, added
2,2,2,4′-trifluoroacetophenone (0.60 g, 3.35 mmol) and
MeOK (0.47 g, 6.70 mmol). The reaction was slowly
warm to room temperature whilst stirring for 20 h – so-
lution A. To a solution of NaBH4 (0.51 g, 13.4 mmol) in
DME (10 mL) at 0 °C was added a 2 M solution of
ZnCl2 in Et2O (8.03 mL). The mixture was allowed to
age for 20 h –solution B. Solution A was cooled to -40 °
C, diluted with MeCN (28 mL) and slowly added solu-
tion B over 20 min, then stirred at -40 °C for 2.5 h. The
reaction was quenched with acetone (40 mL) over 20
min and then warmed to room temperature. The mix-
ture was poured into an ice/water mix (250 mL), the pH
was adjusted to 5 with 1 N HCl and extracted with
EtOAc (200 mL ×3). The organic extracts were washed
with brine (400 mL), dried over Na2SO4 and concen-
trated. Dissolved in DMF (15 mL), added 1-amino-1-
cyclopropanecarbonitrile hydrochloride (0.39 g, 3.35
mmol), HBTU (1.59 g, 4.20 mmol) and NMM (0.54 mL,
4.00 mmol) and stirred at room temperature for 20 h.
Diluted the reaction with water (120 mL) and extracted
with EtOAc (100 mL ×2). The combined organic ex-
tracts were washed with 5 % brine (120 mL ×2) and
brine (140 mL), dried over Na2SO4 and concentrated.
The residue was purified by column chromatography (40 g
column) using 0 to 75 % EtOAc in hexanes to afford (S)-N-
(1-cyanocyclopropyl)-3-(methylthio)-2-(((S)-2,2,2-trifluoro-
1-(4-fluorophenyl)ethyl)amino)propanoate as a clear
colourless oil (0.36 g, 29 %). To a solution of (S)-N-(1-cya-
nocyclopropyl)-3-(methylthio)-2-(((S)-2,2,2-trifluoro-1-(4-
fluorophenyl)ethyl)amino)propanoate (0.34 g, 0.91 mmol)
in EtOAc (8.78 mL) was added NaTg•2H2O (3.56 mg, 0.01
mmol) and TBAH (15.6 mg, 0.05 mmol) followed by
addition of H2O2 (30 % w/w in water, 0.23 mL). The
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reaction was stirred at room temperature for 3 h. Diluted
the reaction mixture with EtOAc (70 mL) and washed with
a solution of 2 M Na2S2O3 (100 mL ×2) and brine (100
mL), dried over Na2SO4 and concentrated to afford (S)-N-
(1-cyanocyclopropyl)-3-(methylsulfonyl)-2-(((S)-2,2,2-tri-
fluoro-1-(4-fluorophenyl)ethyl)amino) propanoate (com-
pound 6) as a white powder (0.29 g, 79 %); 1H-NMR (400
MHz, d6-DMSO) δ 9.05 (s, 1H), 7.45 (dd, J = 8.0, 6.0 Hz, 2H),
7.25 (dd, J = 8.0, 6.0 Hz, 2H), 4.37 (quintet, J = 8.0 Hz, 1H),
3.74-3.66 (m, 1H), 3.54-3.46 (m, 2H), 3.17 (dd, J = 16.0, 4.0
Hz, 1H), 3.12 (s, 3H), 1.42-1.33 (m, 2H), 1.05-0.98 (m, 1H),
0.79-0.74 (m, 1H); LC-MS > 98 %,m/z = 408.12 [M + H].
Inhibition of cathepsin activity using compound 6
Inhibition of cathepsin activity using compound 6 Re-
combinant cathepsin activity: Analysis of recombinant
cathepsin activity was performed in a 96-well plate. All
assays were performed in triplicate in the presence of so-
dium acetate assay buffer (sodium acetate 100 mM,
EDTA 1 mM, Brij 0.1 %, and Dithiothreitol 2 mM, pH
5.5). Recombinant CTSS (4 nM), K (4.25 nM), V (4 nM),
L (4 nM) and B (3.5 nM) (Calbiochem, UK) was incu-
bated with compound 6 at a range of concentrations.
The concentration of recombinant protein used in these
assays was assumed to be equivalent to the active en-
zyme concentrations. Cathepsin activity was monitored
using peptidyl fluorescent substrates; Cbz-VVR-AMC
(20 μM, CTSS), Cbz-FR-AMC (20 μM, Cathepsins K, V
and at 5 μM for cathepsin L) and Cbz-RR-AMC (20 μM,
cathepsin B). Protease activity was monitored over the
period of 1 h using a fluorometer (Flurostar Optima)
with excitation at 390 nm and emission at 460 nm. Pro-
gress curve data points generated by compound 6 were
fitted to equation 1 using GraphFit software.
v ¼ vo
E½ − I½ −Ki appð Þ þ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
E½ − I½ −Ki appð Þ
 2 þ 4 E½ :Ki appð Þ
q
2 E½ 
ð1Þ
Where, vo is the steady state rate, E is the enzyme con-
centration and I is the inhibitor concentration. Using this
equation values of v were generated for each concentration
of inhibitor. Using these values, Morrison Plots were subse-
quently produced (v versus [I]), allowing determination of
Ki (app) values. To account for any completing substrate
these values were corrected using equation 2, allowing the
generation of true Ki values for compound 6 versus cathep-
sins S, K, V, L and B.
Ki ¼ Ki appð Þ= 1þ S½ Km
 
ð2Þ
Cathepsin activity in lysates: For analysis of CTSS-like
activity in MC38 cell lysates, MC38 cells were grown to
confluency, harvested and lysed on ice using sodium
acetate lysis buffer (Sodium acetate 100 mM, sodium
chloride 100mM, Triton X-100 0.1 %, pH 5.5). Lysates
were quantified by BCA, before addition to black-
bottom 96-well plate at 100 μg per well. The lysates
were incubated in 100 mM phosphate buffer (pH 7.5) at
37 °C for 1 h to inactivate cathepsins B and L. Following
this step, the lysates were incubated in MES buffer (MES
500 mM, EDTA 1mM, Dithiothreitol 2 mM, pH 5.5) to re-
turn the pH to 6, compound 6 added, and the lysates incu-
bated for 30 min at 37 °C. The lysates were then evaluated
for CTSS-like activity using 20 μM Cbz-VVR-AMC and
fluorogenic substrate turnover monitored over the period
of 1 h using a fluorometer (Flurostar Optima) as described
above. The result was presented in triplicate, expressing
relative fluorescent units versus time in minute ± SEM.
Western blotting
Western blotting was carried out as previously described
[29] using the following primary antibodies: mouse anti-
human CD74 (1:400) (sc-47741, Santa Cruz, USA [30]), rat
anti-mouse CD74 (1:1000) (555317, BD Biosciences, USA
[31]) and rat anti-α-tubulin (1:10000) (ab6160, Abcam, UK
[32]). The membrane was subsequently incubated with ap-
propriate secondary antibody; goat anti-mouse HRP conju-
gate (1:10000) (172-1011, BioRad, UK [29]) or rabbit anti-
rat HRP conjugate (1:40000) (ab102199, Abcam, UK [29]).
Proteins were detected by chemiluminescence protocol and
exposed using the BioRad Molecular Imager ChemiDoc
XRS+ Imaging System (BioRad, USA).
Invasion assays
A 24-well transwell plate (Corning, UK) containing 8.0
μm polycarbonate membrane was coated with Matrigel
(1 mg/mL) (BD Biosciences). MC38 and MCF7 cells
were seeded into the upper well at a density of 2.5x105
per well in serum-free media in the presence of com-
pound 6 at a range of concentrations and invasiveness
evaluated as previously described [24]. Each condition
was performed in duplicate, with 9 images taken per
membrane at X20 magnification. Images were analysed
using ImageJ and figures were generated using GraphPad
Prism. Results demonstrate the mean number of cells
per field of view per group ± SEM. Statistical analysis
carried out by analysis of variance with Tukey test com-
paring all conditions.
Endothelial tube formation assay
A 48-well plate was coated with Matrigel (10 mg/mL)
and incubated at 37 °C for 1 h. 1×105 HUVECs were
seeded per well in triplicate, treated with compound 6
(100 nM/10000 nM) and incubated for 18 h. Imaging
was performed using a Nikon Eclipse microscope with
six images taken from triplicate wells and analysis
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carried out using ImageJ. Figures were generated using
Graphpad Prism displaying the average total tubule
length per field of view. The result was expressed as the
mean total tubule length per group ± SD. Statistical ana-
lysis carried out by analysis of variance with Tukey test
comparing all conditions.
Lentiviral generation of stable shRNA lines
CTSS knock down construct sh835 was purchased from
Sigma Aldrich, UK and were transduced into MC38 cells
using lentiviral particles as previously described [6].
MC38 cells containing knockdown construct were con-
tinuously selected for using puromycin (6 μg/mL). Suc-
cessful knock-down of CTSS was confirmed by RT-PCR.
RT-PCR
RNA was extracted using STAT - 60 (Biogenesis, UK) ac-
cording to manufacturer’s protocol and cDNA generated
using Improm-II reverse transcriptase kit (Promega, UK)
as previously described [29]. For amplification of the
CTSS and GAPDH cDNA, the following primer sets were
used: CTSS forward primer 5′ GGGATCTCTGGAAGAA
AACCC’3 and reverse primer 3′- TTCGGAGACTGTCG
GGGAAT’5. GAPDH forward primers 5′-AAGGTCATC
CCAGAGCTGAA-3′ and reverse primer 3′CTGCTTCA
CCACCTTCTTGA-5′.
In vivo evaluation of CD74 degradation in murine spleens
All mice used in these experiments were supplied
with housing and subsequent experimentation was
carried out in accordance with the Animal (Scientific
Procedures) Act 1986, following UKCCCR guidelines
and approved by the Ethical Review Committee with
Queen’s University Belfast. 20 week old C57BL/6 mice
were intraperitoneally injected with either compound
6 (100 mg/kg) or control. Spleens were harvested
after 18 h and homogenized in RMPI1640 using
nylon mesh. Red blood cells were lysed using ammo-
nium chloride potassium (ACK) lysis buffer. Whole
splenocytes were then lysed and protein analysed by
western blot using rat anti-mouse CD74 antibody, as
described previously.
MC38 syngeneic model
Six to eight week old C57BL/6 mice were subcutane-
ously injected with 5.0×106 MC38 cells resuspended in
growth factor reduced matrigel (4 mg/ml, diluted in ster-
ile PBS) into the right flank on day 0. Upon tumors
reaching 100 mm3, mice were then treated with com-
pound 6 (2 mg compound 6 in 4 % DMSO: 96 % peanut
oil; 100 mg/kg) or vehicle control (4 % DMSO: 96 %
peanut oil) via intraperitoneal injection every 2 to 3 days.
Tumor volumes were calculated as Volume = length ×
breadth × π/6 (n = 5/group). Data was presented as mean
tumor volume per group ± SEM. Statistical analysis
carried out by student’s t test. Blood serums were sam-
pled at day 13 from mice and subjected to CCL2 ELISA
(R&D Systems, UK) as previously described [6].
MCF7 xenograft model
Six to seven week old BALB/c nude mice were subcuta-
neously injected with an oestrogen pellet (approx 0.5
mg). 10 days later, mice were subcutaneously injected
with 3.0x106 MCF7 cells suspended in Matrigel (4 mg/
ml, diluted in PBS). Upon tumors reaching 100 mm3,
mice were then treated with compound 6 (2 mg com-
pound 6 in 4 % DMSO: 96 % peanut oil; 100 mg/kg) or
vehicle control (4 % DMSO: 96 % peanut oil) via intra-
peritoneal injection every 2 to 3 days. Tumor volume
was calculated as described previously (n = 6/group).
Data was presented as the mean tumor volume per
group ± SEM. Statistical analysis carried out by student’s
t test.
Immunohistochemistry
MCF7 tumor sections (6 µm) were formalin fixed, paraffin-
embedded and subjected to immuno-staining as previously
described [16]. Sections (n = 4/group) were incubated in
rabbit anti-human Ki67 primary antibody (1:300)
(ab155580, Abcam, UK [16]). Slides were subsequently
stained with biotinylated goat anti-rabbit (1:300) (BA-1000,
Vector, UK [16]) secondary antibody. The number of Ki67
positive cells was assessed by random selection of 10 fields
of view per tumor under X20 magnification using a Leica
DM5500B microscope and AL software. The number of
Ki67 positive cells was presented as the mean Ki67 positive
cells ± SEM. Statistical analysis carried out by student’s t
test.
TUNEL staining
Paraffin-embedded MCF7 tumor sections (6 μm) were
stained for apoptosis using terminal deoxynucleotidyl
tranferase-mediated dUDP-nick-end labelling (TUNEL)-
based TumorTACS™ In Situ Apoptosis Detection Kit (R&D
Systems, UK [16]) as per the manufacturer’s instructions.
TUNEL staining was assessed by random selection of 10
fields of view per tumor under a X20 magnification using a
Leica DM5500B microscope and AL software. The number
of TUNEL positive cells were counted and presented as the
mean TUNEL positive cells ± SEM. Statistical analysis car-
ried out by student’s t test.
MTT cell viability assays
Effects on cell proliferation following compound 6
treatment or presence of knock-down construct sh835
were assessed by MTT assays as previously described
[6]. Absorbance values were measured at 570 nM and
results presented as mean ± SD.
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Results
Evaluation of CTSS clinical candidate inhibitor
To assess the inhibition of both intra- and extracellular
CTSS in our models we synthesized a dipeptide nitrile
based inhibitor (compound 6), previously reported as a
potent and selective inhibitor of human and murine
CTSS (Fig. 1a) [26]. This compound has been previously
used to investigate the therapeutic potential of CTSS in
atherosclerosis [27]. The compound was synthesized in-
house and its effectiveness against a panel of human
cathepsin recombinant proteases was assessed.
Analysis of fluorimetric substrate turnover by CTSS
demonstrated that compound 6 blocked CTSS activity in
a concentration dependent manner (Fig. 1b). Furthermore
compound 6 inhibited the activity of recombinant cathep-
sins K, V and B to varying degrees with limited activity
against L (Fig. 1c-f). We then determined the Ki of com-
pound 6 against each of these enzymes and subjected to
non-linear analysis and fitted to Morrison kinetics [33].
This demonstrated that there was a high preference of
compound 6 towards human recombinant CTSS (2.71
nM) over the other closely related proteases (CTSK 155
nM; CTSV 784 nM; CTSL 7870 nM; CTSB 1940 nM)
(Additional file 1: Figure S1), in agreement with previously
reported IC50 selectivities [26].
Compound 6 blocks intracellular degradation of lip10
To assess the effect of compound 6 on CTSS activity in a
more complex milieu, we firstly incubated the inhibitor
with murine MC38 colorectal carcinoma cell lysates, and
measured turnover of a fluorogenic substrate Cbz-VVR-
AMC. Addition of compound 6 to MC38 lysates demon-
strated a concentration dependent reduction in CTSS-like
activity (Fig. 2a).
Next we assessed the effectiveness of the inhibitor to-
wards a physiologically relevant substrate. The invariant
chain (CD74) is a known intracellular substrate of CTSS
and when CTSS activity is ablated through inhibition or
deletion, it leads to accumulation of a 10 kDa invariant
chain fragment (lip10) [34, 35]. Thus, monitoring of this
fragment in antigen presenting cells can inform the ability
of CTSS inhibitors function within the cell. Raji cells were
treated with compound 6 and the accumulation of the
lip10 fragment was analysed by western blot (Fig. 2b).
Semi-quantitative analysis of these bands by densitometry
revealed compound 6 to have an IC50 of 2.9 μM (Fig. 2c).
Inhibition of CTSS blocks tumor cell invasion and
endothelial tube formation
Previously we have demonstrated the effect of blocking cell
invasion through CTSS shRNA mediated depletion using
Fig. 1 Compound 6 blocks recombinant CTSS in a concentration dependent manner. a Structure of compound 6. Inhibitory activity of
compound 6 versus b) recombinant CTSS, inset: Morrison plot for calculation of Kic-f) Inhibitory activity of compound 6 versus recombinant
cathepsin K, V, L and B was measured by fluorescent peptidyl substrate assay
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MC38 cells [16]. Here we found that treatment with com-
pound 6 resulted in a dose dependent inhibition of MC38
cell invasion (Fig. 3a). In parallel to these experiments, we
assessed potential cytotoxic effect of compound 6 on MC38
cells at these concentrations, finding no significant effect on
cell viability (Additional file 2: Figure S2). Taken together
this indicated that compound 6 inhibited migration of the
cells through the artificial ECM layer by blocking invasion
as opposed to an anti-proliferative or cytotoxic effect.
To further evaluate the selectivity of compound 6, we
decided to utilise an MC38 CTSS knock-down cell line,
achieved through stable transfection of sh835 [6], to evalu-
ate the effect versus a non-targeting control (NTC)
shRNA. The sh835 CTSS knock-down line was validated
by RT-PCR (Fig. 3b). The sh835 knock-down cells proved
less invasive as anticipated versus the NTC cells (Fig. 3c).
Furthermore, treatment of the NTC cells with compound
6 resulted in a reduced level of cell invasion comparable
to the sh835 cells. Importantly, treatment of the sh835
cells with compound 6 demonstrated no additional reduc-
tion in the invasion, strongly indicating selectivity of com-
pound 6 towards CTSS. MTT analysis indicated no effect
of compound 6 on cell viability on either the MC38 NTC
or sh835 cell lines (Additional file 3: Figure S3).
We have previously demonstrated in vitro that CTSS
inhibition can attenuate endothelial tube formation, a
process that underpins neoangiogenesis [36]. HUVEC
cells were plated out on Matrigel coated plates and tube
formation quantified after 18 h. Treatment of these cells
with compound 6 elicited a mild but significant reduc-
tion in average tubule length at 100 nM (Fig. 3d). Taken
together these in vitro studies demonstrate that com-
pound 6 could inhibit CTSS to block pro-tumorigenic
characteristics of tumor and endothelial cells, warranting
further investigation with in vivo models.
Evaluation of compound 6 in murine MC38 syngeneic
model
To ensure that dosing of compound 6 in vivo would suf-
ficiently block tumor CTSS, we first evaluated the ability
of compound 6 to block lip10 degradation in C57BL/6
mice spleens upon administration. Mice were treated
with compound 6 (100 mg/kg) and the level of CD74
degradation in their splenic lysates was evaluated. These
experiments revealed a clear accumulation of lip10 frag-
ment in mice (group of three) treated with compound 6
in comparison to mice treated with vehicle control
(Fig. 4a). Extrapolation of band strength furthermore re-
vealed lip10 band strength to be increased by ~13.13-
fold, consistent with the effect observed in vitro using
the Raji cells (Additional file 4: Figure S4).
Fig. 2 Compound 6 reduces MC38 CTSS-like activity and blocks intracellular degradation of CD74. a MC38 cells were lysed and treated with
compound 6 demonstrating reduction of CTSS-like activity b) Compound 6 permeated the cell membrane of human Raji cells and blocked
degradation of CD74 fragment lip10, a canonical endosomal CTSS substrate. c Evaluation of lip10 band intensity revealed an IC50 value of 2.9 µM
for compound 6
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We then examined the effect of compound 6 treatment
on mice bearing MC38 syngeneic colorectal adenocarcin-
oma tumors. This model provides a fully immunocompe-
tent microenvironment and we have used this model
previously in our genetic ablation studies examining contri-
bution of CTSS to tumor growth when derived from the
tumor and/or the stoma [16]. We monitored MC38 tumor
growth over a 16 day period with treatment of compound 6
or vehicle control delivered via intraperitoneal injection
starting on day zero and following every 2 to 3 days. Dosing
of compound 6 resulted in a reduction in tumor progres-
sion of approximately 50 % by day 16 when compared to
vehicle-treated controls (Fig. 4b), an effect similar to what
we had previously observed with CTSS depletion [16]. The
weights of these animals were also monitored during the
treatment timecourse, confirming no adverse effects of the
inhibitor on mice weight and appearance (Additional file 5:
Figure S5). During the course of this study, we also analysed
serums from the tumor bearing animals and assessed CCL2
levels. Consistent with our previous report that CTSS in-
hibition can block CCL2 production [6], here we found a
reduction in CCL2 levels at day 13, 24 h after the 5th ad-
ministration of compound 6 (Additional file 6: Figure S6).
Evaluation of compound 6 on human MCF7 xenograft
tumors
Previously we have examined the inhibition of CTSS in
human astrocytoma and colorectal tumors [24], but
Fig. 3 Compound 6 blocks CTSS mediated MC38 cell invasion and HUVEC endothelial tube formation. a Compound 6 attenuates MC38 invasion
Left: Treatment of MC38 cells with 1000 nM compound 6 significantly reduced tumor cell invasion as determined by measuring invaded cells per
field of view (pfv) (**P<0.01). Right: representative images. To evaluate compound 6 selectivity in a cellular assay, murine colorectal cell line MC38
was transfected with either a non-targeting construct (NTC) or CTSS knock-down construct (sh835). b Diminished CTSS expression was confirmed
by RT-PCR. c The invasiveness of the MC38 NTC and sh835 cells was analysed by transwell assay. MC38 sh835 cells demonstrated reduced invasive
potential compared to the MC38 NTC cells (***P<0.001). Treatment of MC38 NTC cells with compound 6 (1000 nM) resulted in a significant reduction in
invasion (***P<0.001). No further effect was observed with treatment of MC38 sh835 cells with compound 6 (1000 nM). d Left: Compound 6 significantly
reduced HUVEC endothelial tube formation approximately 10 % from 100 nM (***P<0.001). Right: representative images
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recently Sevenich and colleagues have shown that CTSS
inhibition may also have utility in breast cancer [19].
MCF7 cells are oestrogen dependent adenocarcinomas
that have previously been shown to express CTSS [37],
and have previously been used as a model of tumor
invasion in a number of other studies [38–41]. Taking
these findings together, we examined whether the anti-
tumor effects of compound 6 translated to a more
human relevant model. Indeed, evaluation of com-
pound 6 on MCF7 cell invasion demonstrated a dose
dependent reduction in tumor cell invasion (Fig. 5a);
which was independent of any effects on cell viability
(Additional file 7: Figure S7).
The impact of compound 6 in vivo was then evaluated
in the MCF7 xenograft model. The treatment of the
mice resulted in a 30 % reduction of tumor growth by
day 29 compared to vehicle-treated controls (Fig. 5b).
To determine any affect on the health of the mice, their
weights were obtained at the beginning of the study and
treatment with compound 6 did not affect the health of
the mice (Additional file 8: Figure S8).
Upon completion of the xenograft study, the mice
were sacrificed, tumors harvested and MCF7 tissue sec-
tions prepared and stained for proliferation marker Ki67.
Evaluation of Ki67 positive cells revealed that cell prolif-
eration was significantly reduced in the compound 6
treatment group (Fig. 5c). Evaluation of compound 6
effect on neo-angiogenesis was also carried out by CD34
staining, however, no observable differences could be
confirmed between mice treated with compound 6 and
control mice (Data not shown). Finally, the presence of
apoptotic cells was evaluated using TUNEL staining.
The results demonstrated an increased level of apoptosis
in the compound 6 treated MCF7 tissue sections when
compared with vehicle-treated controls (Fig. 5d). Taken
together, CTSS inhibition was shown to block tumor
progression, through decreased invasion, decreased
proliferation and increased apoptosis, consistent with
previous observations [16].
Discussion
In this report we have described the validation and charac-
terisation of small molecule CTSS inhibitor, compound 6
using activity, cellular and murine tumor models. We vali-
dated selectivity of compound 6 towards CTSS using a re-
combinant enzyme activity screening before confirming its
effect on cellular activity. Compound 6 demonstrated the
ability to block both murine and human cell invasion and
to disrupt endothelial tube formation showing its activity
as an anti-angiogenic compound. Selectivity of compound
6 towards CTSS in the cellular environment was confirmed
using an MC38 knock-down model, whereby treatment of
CTSS depleted cells with compound 6 produced no further
reduction in invasion. The efficacy of compound 6 was vali-
dated in vivo, first demonstrating inhibition of murine
spleen CTSS and subsequently using MC38 syngeneic and
MCF7 xenograft tumor models, where compound 6 treat-
ment demonstrated reduced tumor volume, complemented
by reduced cell proliferation and concomitant increase in
apoptosis.
Over the past 15 years, there has been an increasing
body of evidence reporting increased expression of
CTSS in a variety of malignancies [42–44], with this in-
creased expression being associated with poorer progno-
sis in grade IV astrocytomas and colorectal carcinomas
[13, 14]. Genetic ablation studies targeting CTSS has
demonstrated reduced tumor progression in murine
models [15, 16]. Indeed, CTSS has been shown to cap-
able of degrading a number of substrates including ECM
proteins, pro-and anti-angiogenic substrates, proteins in-
volved in metastases and pro-inflammatory cytokines/
chemokines [5, 6, 17–19].
Fig. 4 Compound 6 blocks CD74 degradation in murine spleen and reduces progression in MC38 tumor model. a C57BL/6 mice were treated
with 100 mg/kg compound 6 for 18 h before harvesting of spleens and subsequent analysis of CTSS substrate lip10 by western blot. Results
demonstrated compound 6 to block CTSS degradation of lip10 in murine spleen (3 mice/group). b Treatment of MC38 tumors syngeneic model
with compound 6 (on days indicated by black arrow) significantly reduced tumor volume over 16 days (*P<0.05; **P<0.01)
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Compound 6 was previously reported to be a potent
and selective CTSS inhibitor [26]. Generation of Ki values
for compound 6 versus CTSS and family members K, L
and B (Additional file 1: Figure S1) were consistent with
IC50 values previously reported [26]. Importantly, this in-
hibitor demonstrated membrane permeability and cross
species reactivity by blocking lip10 degradation both in
vitro using Raji cells and subsequently in vivo in C57BL/6
spleen tissue [27] and indicating suitability of compound 6
as a tool compound to aid the elucidation of CTSS in sub-
sequent experiments. When applied in both MC38 and
MCF7 transwell invasion assays, compound 6 demon-
strated the ability to reduce tumor cell invasiveness in a
manner consistent with pharmacologically blocking CTSS
activity [24].
The inhibitor used here has previously been utilised
in vivo in Apoe-/- mice, observing the effect of CTSS in
lung granuloma, atherosclerotic lesions [27, 28] and in
a murine asthma model [45]. Here, the effectiveness of
compound 6 in vivo was validated in murine cancer
models for the first time. The role of CTSS in colorec-
tal tumors has been well elucidated in patients, with
high expression indicating poorer prognosis [14]. A
dual depletion MC38 model has previously been
established, whereby both host and tumor CTSS has
been depleted, demonstrating a reduction in tumor
Fig. 5 Compound 6 reduces MCF7 tumorigenesis in vitro and in vivo. a Compound 6 demonstrated a significant concentration dependent
reduction in MCF7 invasion from 100 nM (***P<0.001). b MCF7 cells were propagated in BALB/c nude mice and subsequently treated with
compound 6 (100 mg/kg) over the course of 29 days, indicated by black arrows. Treatment with compound 6 caused a significant reduction in
tumor volume of 31 % versus vehicle by day 29 (**P<0.01). Immunohistochemical analysis of proliferation was carried out on MCF7 tumor
sections. c Compound 6 caused a significant 0.62-fold reduction in tumor proliferation (***P<0.001), as demonstrated in the representative
images. d TUNEL analysis of apoptosis was carried out on the MCF7 tumor sections. Compound 6 treatment demonstrated a 1.60-fold increase of
apoptosis within the tumor sections (***P<0.001), as demonstrated in the representative images
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progression and growth [16]. Consistent with this, com-
pound 6 demonstrated a reduction in tumor volume
using a matching MC38 synergistic tumor model. Inter-
estingly, a greater reduction in tumor volume was ob-
served in the MC38 model than the MCF7 model. It is
possible that this may be a consequence of harbouring the
tumors in immunocompromised BALB/c mice, which are
lacking some stroma-mediated interactions [46, 47].
Recently, a role for CTSS has been uncovered with
respect breast-to-brain metastasis. Inhibition using a
CTSS inhibitor VBY-999, reduced CTSS mediated me-
tastases in an MDA-MB-231 triple negative breast
cancer model [19]. Interestingly, in contrast to our
own observations using a luminal A MCF7 model, no
reduction in tumor burden was observed with respect
the MDA-MB-231 xenograft and VBY-999 treatment
[19], suggesting that classical CTSS pathological roles
in ECM degradation and neo-angiogenesis may be
subtype specific, warranting a more in-depth analysis
of breast cancer heterogeneity at the patient sample
level.
Compound 6 demonstrated only a mild anti-angiogenic
effect in vitro against HUVEC tube formation. Interestingly,
this effect was not as pronounced as previously observed
with FSN0503 [24]. CTSS has been shown to play a key
role in neo-vascularisation at the tumor site [24, 34, 48, 49].
Previously, depletion of CTSS in vivo has also demon-
strated a reduction in angiogenesis using an MC38 syngen-
eic model [16]. Analysis of harvested MCF7 tumors using
CD34 vascular marker did not demonstrate a difference be-
tween groups (data not shown). This is perhaps unsurpris-
ing due to the smaller effect exhibited by compound 6 on
HUVEC tube formation in comparison to FSN0503. As a
result, further analysis, possibly using a cell line that ex-
hibits higher levels of vascularisation than these MCF7 tu-
mors, may reveal further anti-tumorigenic effects.
Conclusions
In conclusion, small molecule inhibitor compound 6 dem-
onstrates the ability to block tumor progression both in
vitro and in vivo. Our results compliment previous obser-
vations in colorectal carcinomas and furthermore, have
demonstrated for the first time, blockade of tumor pro-
gression in a breast cancer murine model. The reduction
in tumor progression caused by CTSS inhibition necessi-
tates further analysis of expression in human clinical sam-
ples, to identify patients who would benefit from CTSS
inhibition. Indeed, in the past chemotherapeutic and radi-
ation treatment has resulted in increased expression of
CTSS likely due to cellular stress [22, 37, 50], suggesting
inhibition of CTSS may be crucial for patient outcome.
We hypothesize, that the development of small molecule
CTSS inhibitor compound 6 will facilitate the understand-
ing of mechanistic roles for CTSS in disease and
furthermore, facilitate its characterisation in cancers
which are currently poorly defined.
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